TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives $7.80 Average Target Price from Analysts
TScan Therapeutics, Inc. (NASDAQ:TCRX – Get Free Report) has been given a consensus rating of “Buy” by the five brokerages that are currently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have updated their coverage on the stock in […]
TScan Therapeutics, Inc. (NASDAQ:TCRX – Get Free Report) has been given a consensus rating of “Buy” by the five brokerages that are currently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have updated their coverage on the stock in […]
